{"id":"dfp-10917","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL5095369","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, DFP-10917 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. Its exact mechanism of action is not fully understood, but it is believed to work by reducing glucose reabsorption in the kidneys.","oneSentence":"DFP-10917 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:19.627Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT06382168","phase":"PHASE1, PHASE2","title":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2024-06-12","conditions":"Leukemia, Myeloid, Acute","enrollment":39},{"nctId":"NCT03943004","phase":"PHASE1","title":"Trial of DFP-14927 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-09-30","conditions":"Solid Tumor, Cancer","enrollment":30},{"nctId":"NCT01702155","phase":"PHASE1, PHASE2","title":"Phase I/II Study of DFP-10917 in Patients With Acute Leukemia","status":"COMPLETED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2012-10-10","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DFP-10917","genericName":"DFP-10917","companyName":"Delta-Fly Pharma, Inc.","companyId":"delta-fly-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DFP-10917 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}